Brilinta/Brilique enters Phase III trial for Peripheral Artery Disease - AstraZeneca
AstraZeneca has announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying Brilinta/Brilique (ticagrelor) tablets. Part of PARTHENON, AstraZeneca's largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with Peripheral Artery Disease (PAD); approximately 20 percent are patients in the United States (US) from more than 300 active clinical trial sites across the country.
EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins